Nadia Ahmad, MD, MPH is the associate vice president of medical development for obesity therapeutics at Eli Lilly and Company. She is responsible for leading the Phase 3 clinical development programs for nutrient-stimulated hormone-based therapies, including tirzepatide, retatrutide, and orforglipron, in people living with obesity.
Nadia joined Lilly in February 2019 as a senior medical advisor of obesity product development. In her role as senior medical advisor, Nadia drove several internal engagement programs in obesity and contributed to cross-functional efforts for obesity strategy, in addition to serving as the lead for two of the four phase 3 SURMOUNT registration trials. Prior to joining Lilly, Nadia was the founding director of the Obesity Medicine Institute in Dubai and held the role of senior advisor of obesity solutions at Johnson & Johnson Middle East.
Nadia earned her medical degree from New York University School of Medicine and completed an Internal Medicine Residency at the University of Pennsylvania. She went on to become an inaugural fellow in the nation’s first Obesity Medicine and Nutrition fellowship program at the Massachusetts General Hospital. Nadia also holds a Master of Public Health from the Harvard School of Public Health. She is passionate about transforming care for people living with obesity.